Beta-Alanine (3-Aminopropanoic Acid)

1. Generic or Accepted Substance Name & Classifications

Accepted Name: Beta-Alanine (3-Aminopropanoic Acid)
Common Names, Synonyms & Classifications: β-Alanine; 3-Aminopropionic Acid; Intracellular Carnosine Rate-Limiting Precursor
Section Classification: Group A — Evidence-Supported Sports Nutrition & Ergogenic Aids (PERF-A03)

2. Pharmacological Class

Non-Proteinogenic Beta-Amino Acid & Intramuscular Histidine-Dipeptide (Carnosine) Precursor

3. Mechanism of Action

Beta-alanine is the rate-limiting substrate for hepatic and skeletal muscle carnosine synthase, which combines beta-alanine with L-histidine to form intracellular carnosine (beta-alanyl-L-histidine). Because the imidazole ring of carnosine has a pKa of ~6.83 (close to physiological intracellular pH), elevating muscle carnosine by 40–80% over 4–10 weeks buffers intracellular H⁺ accumulation during intense anaerobic glycolysis.

4. Proposed Performance or Endurance Effects (Pharmacological Effect vs Proven Athletic Outcome)

Pharmacological Effect: Chronic loading increases skeletal muscle carnosine concentration. Proven Athletic Performance Benefit: Modest but consistent ergogenic improvements (1–3%) in high-intensity exercise tasks lasting 30 seconds to 10 minutes (e.g., 400m–1500m track running, 100m–400m swimming, rowing, and combat sports) where intramuscular acidosis limits contraction. Unsupported Claims: Taking a single acute pre-workout dose of beta-alanine on race day has zero ergogenic effect because muscle carnosine loading requires weeks of cumulative intake.

5. Quality of Scientific Evidence

Evidence Assessment: High to Moderate / Level A–B Consensus (IOC Consensus Statement & ISSN Position Stand on Beta-Alanine)

6. Approved Medical Uses (Where Applicable)

No approved prescription medical indication; used strictly as a sports nutrition buffering supplement.

7. Sports-Related Uses, Misuse Patterns & Contamination Risks

Evidence-based loading uses divided daily intakes (e.g., 3.2–6.4 g/day split into 0.8–1.6 g doses or sustained-release tablets over 4–12 weeks). Misuse occurs when athletes ingest large single bolus doses (>2–3 g at once) in pre-workout powders expecting acute stimulation, mistaking the resulting skin tingling (paraesthesia) for an immediate performance boost.

8. Adverse Effects & Serious Safety Risks

Acute transient non-allergic paraesthesia (prickling, flushing, or tingling of the face, neck, and hands lasting 30–60 minutes) mediated by activation of cutaneous Mas-related G-protein-coupled receptor D (MrgprD) on sensory neurons when single doses exceed ~800 mg.

9. Contraindications & Precautions

Hypersensitivity to formulation excipients; pregnancy and lactation (insufficient safety data); rare inborn disorders of beta-amino acid metabolism (hyper-beta-alaninaemia).

10. Drug Interactions

Shares the beta-amino acid transporter (TauT / SLC6A6) with taurine; theoretical competition at extreme experimental doses, though standard human loading protocols do not cause clinically significant myocardial taurine depletion. May have additive buffering effects when combined with Sodium Bicarbonate.

11. Clinical & Laboratory Monitoring Considerations

Use divided doses or sustained-release formulations to minimise MrgprD-mediated paraesthesia; verify third-party anti-doping batch certification.

12. Dependence, Misuse or Withdrawal Concerns

No dependence, tolerance, or withdrawal. Muscle carnosine washout is slow (~2% per week, taking 6–15 weeks to return to baseline).

13. Regulatory & Legal Status in India (CDSCO / Drugs Rules / NDPS / FSSAI)

Permitted sports nutrition amino acid ingredient under FSSAI Nutraceutical and Food for Special Dietary Use (FSDU) regulations in India.

14. Official WADA Prohibited-List Status

NOT PROHIBITED (Permitted at all times under the WADA Prohibited List).

15. Authoritative Source References & Date of Last Verification